AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
MWN-AI** Summary
AIM ImmunoTech Inc. has announced a 1-for-100 reverse stock split, effective June 12, 2025, as part of its strategy to boost the stock's market price. The reverse split aims to help the company comply with the NYSE American's listing qualifications by increasing the per-share value of its common stock, which trades under the ticker symbol AIMID on OTC Pink for 20 trading days following the split. This decision follows the approval by stockholders during a Special Meeting on April 30, 2025, where they endorsed potential amendments to the Company's Certificate of Incorporation allowing for such a split.
In practical terms, shareholders will receive cash for any fractional shares resulting from the split. The newly adjusted shares will have a new CUSIP number (00901B303), while the par value remains fixed at $0.001 per share.
AIM ImmunoTech, based in Ocala, Florida, is an immuno-pharmaceutical company that develops therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. Its lead product, Ampligen® (rintatolimod), is a pioneering investigational drug recognized for its potential in clinical trials targeting significant cancers and viral diseases.
The company emphasizes that the information presented includes forward-looking statements, which involve inherent risks and uncertainties. While the progress made in clinical trials is promising, it does not guarantee regulatory approval for Ampligen in any indication. AIM encourages investors to review the risk factors outlined in their most recent SEC filings. For further details, stakeholders can visit their official website and social media platforms.
MWN-AI** Analysis
AIM ImmunoTech's announcement of a 1-for-100 reverse stock split is significant for investors to consider in relation to the company's strategic objectives. This move aims to elevate the company’s stock price to meet the NYSE American’s listing requirements, which is a crucial milestone for AIM to regain broader market access and investor confidence.
Historically, reverse stock splits are employed by companies in distress to avoid delisting and to project a rejuvenated corporate image. While this can help stabilize the stock price in the immediate term, it is crucial to recognize that a reverse split does not alter the intrinsic value of the company. Existing shareholders will see their share quantities reduced, but the overall market cap remains unchanged. Thus, fundamental analysis should still dictate investment decisions rather than merely reacting to the split.
Investors should evaluate AIM’s core fundamentals, including its product pipeline, particularly the investigational drug Ampligen. As a first-in-class immuno-modulator with applications in various diseases, its potential clinical success is pivotal for the long-term success of the company. Nevertheless, caution is warranted due to the inherent risks outlined in the company’s filings; historical clinical successes do not guarantee future approvals.
Furthermore, with AIM trading on the OTC Pink post-split, liquidity may be limited, which can impact stock volatility. Investors should monitor trading volume and market sentiment closely.
In summary, while the reverse stock split can be a positive step for AIM ImmunoTech in terms of compliance and potential market perception, diligent analysis of the company's fundamentals and broader market conditions is essential before making investment decisions. Strategic positioning in light of AIM’s long-term prospects and potential risks will be key to a successful investment strategy.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company’s ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date.
One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the NYSE American’s Listing Qualifications.
At a Special Meeting of Stockholders held on April 30, 2025, the Company’s stockholders approved a series of alternate amendments to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at a ratio in the range of up to 1-for-100, with such ratio to be determined by the Company’s Board of Directors. Stockholders will be given cash in lieu of any fractional shares on a post-split basis. Following the Reverse Stock Split, the new CUSIP number of the common stock will be 00901B303, with the par value per share of common stock remaining at $0.001.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
How does AIM ImmunoTech's reverse stock split (AIMI) impact investor perceptions of the company's financial stability and future growth potential in the immuno-pharma sector?
What specific steps is AIM ImmunoTech (AIMI) taking to enhance compliance with NYSE American’s Listing Qualifications following the reverse stock split?
In light of the reverse stock split, how does AIM ImmunoTech (AIMI) plan to address potential investor concerns regarding the clinical success and approval timeline of its lead product, Ampligen?
What are the key milestones that AIM ImmunoTech (AIMI) anticipates post-reverse split that could positively influence shareholder value and market confidence?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
